A total of 2979 European ancestry BRCA1/2 PV carriers with information on PRS and QRFs were eligible for inclusion in the analysis, of whom 209 (127 BRCA1 and 82 BRCA2 PV carriers) developed BC during the 5-year risk prediction period (cohort-1). The gene discussed is BRCA2; the disease is breast cancer.